RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Yohannes Tesfaigzi to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Yohannes Tesfaigzi has written about Xenograft Model Antitumor Assays.
Yohannes Tesfaigzi
Connection Strength
0.022
Xenograft Model Antitumor Assays
  1. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Baylin SB, Reed MD, Tellez CS, March TH. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 2011 Jan 15; 71(2):454-62.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support